PE

Peptron, Inc.

Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.

087010 | KO

Overview

Corporate Details

ISIN(s):
KR7087010005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 37-24, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Peptron, Inc., established in 1997, is a biotechnology company specializing in the development of peptide-based medicines. The company's core focus is its proprietary sustained-release (SR) drug delivery platform technology, known as SmartDepot, which enables the formulation of long-acting medications that can extend a drug's release profile from weekly to monthly intervals. Peptron's development pipeline targets treatments for various chronic, life-threatening, and neurodegenerative disorders. The company is actively developing exenatide as a drug for neurodegenerative conditions, supported by an exclusive license for related NIH patents.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.8 KB
2025-08-05 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-07-28 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.6 KB
2025-07-28 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (PND3174의 제1a상 임상시험계획 자진취하)
Korean 10.6 KB
2025-03-31 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 29.4 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.0 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.4 KB
2025-03-28 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.2 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 17.7 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 473.5 KB
2025-03-19 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 18.6 KB

Automate Your Workflow. Get a real-time feed of all Peptron, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Peptron, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Peptron, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.